Evidence map›Paper›PMID 40055449›Full record

ArticleThe Journal of antibiotics2025

Epiconone, one novel cyclohexenone from endophytic fungi Epicoccum sp. 1-042.

Shanshan Chang, Xinyue Huang, Meng Liu, Ning He, Yan Li, Hu Li, Yihong Li, Mengna Luo, Mengyuan Wang, Xichi Hu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shanshan Chang *CAMS Key Laboratory of Synthetic Biology for Drug Innovation, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.ORCID 0009-0003-6566-0800
Xinyue Huang *CAMS Key Laboratory of Synthetic Biology for Drug Innovation, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.
Meng LiuCAMS Key Laboratory of Synthetic Biology for Drug Innovation, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.
Ning HeCAMS Key Laboratory of Synthetic Biology for Drug Innovation, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.
Yan LiNHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.
Hu LiCAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tiantan xili No.1, Beijing, 100050, People's Republic of China.
Yihong LiCAMS Key Laboratory of Synthetic Biology for Drug Innovation, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.
Mengna LuoCAMS Key Laboratory of Synthetic Biology for Drug Innovation, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.
Mengyuan WangCAMS Key Laboratory of Synthetic Biology for Drug Innovation, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.
Xichi HuDepartment of Laboratory Medicine, Jiangnan University Medical Center (Wuxi No.2 People's Hospital), Wuxi, 214000, People's Republic of China. huxichi@163.com.
Yunying XieCAMS Key Laboratory of Synthetic Biology for Drug Innovation, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China. xieyy@imb.pumc.edu.cn.

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82104047
6 · The paper itself

Abstract

Targeting drug-resistant Acinetobacter baumannii, two fungal strains, Epicoccum sp. 1-042 and Penicillium sp. 19-115, were identified from 35 fungi isolated from Tibet. Bioassay-guided isolation from Epicoccum sp. 1-042 yielded a novel cyclohexenone, epiconone (1), and parasitenone (2), while patulin (3) was isolated from Penicillium sp. 19-115. Structural elucidation was accomplished through comprehensive spectroscopic analysis and quantum chemistry calculations. The biosynthetic pathways of compounds 1 and 2 were proposed based on bioinformatics analysis. Compounds 1 - 3 exhibited antibacterial activity against carbapenem-resistant Acinetobacter baumannii (CRAB) with MIC values ranging from 4 to 128 μg mL

Indexed as

Anti-Bacterial AgentsAscomycotaCyclohexanonesAcinetobacter baumanniiEndophytesMicrobial Sensitivity TestsMolecular StructurePenicilliumAnti-Bacterial AgentsCyclohexanones

Identifiers

PMID40055449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.